# DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

> **NCT03825315** · PHASE2 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 155 (actual)

## Conditions studied

- Plantar Fasciitis

## Interventions

- **BIOLOGICAL:** DAXI 80 U
- **BIOLOGICAL:** DAXI 120 U
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03825315
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-31
- **Primary completion:** 2020-06-04
- **Final completion:** 2020-06-04
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825315, "DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03825315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*